Sign Up to like & get
recommendations!
0
Published in 2019 at "OncoImmunology"
DOI: 10.1080/2162402x.2019.1629260
Abstract: ABSTRACT Background: Tumor mutational burden (TMB) has emerged as an independent biomarker to predict patient responses to treatment with immune checkpoint inhibitors (ICIs) for lung adenocarcinoma (LUAD). MicroRNAs (miRNAs) have a crucial role in the…
read more here.
Keywords:
expression;
mirna based;
signature classifier;
tumor mutational ... See more keywords